Compare GoPro Inc (GPRO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Incyte Corporation — how do they compare? GoPro Inc trades at $0.58 (market cap $114.41M), while Incyte Corporation trades at $120.81 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 214.5× GoPro Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| GPRO | INCY | |
|---|---|---|
Market Cap | $114.41M | $24.54B |
Sector | Technology | Health |
52-Week High | $2.88 | $129.93 |
52-Week Low | $0.62 | $81.61 |
Enterprise Value | $173.19M | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $0.57, down 18.48% in the last session, reflecting ongoing operational challenges. The company shows deteriorating fundamentals with negative net income margins (-28.52%) and consecutive earnings misses. Technical indicators signal bearish momentum, while cash flow remains negative. Recent news highlights a strategic review process for potential sale alternatives as the company faces significant financial stress.
The outlook remains highly speculative with substantial execution risks. Investment opportunity hinges entirely on successful strategic alternatives, while risks include persistent cash burn, competitive pressures, and potential dilution from recent financing. The stock presents a binary outcome scenario dependent on corporate action success.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
